Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

The world's first patient to be treated with personalized gene editing therapy is finally headed home after over 300 days in the hospital. Nine-month-old KJ Muldoon recently underwent CRISPR-based ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

PHILADELPHIA (WPVI) -- After 307 days at the Children's Hospital of Philadelphia, a local baby who was born with a rare and usually fatal disorder is now at home. It's all thanks to a pioneering ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...

CRISPR Therapeutics (CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common ...

The Influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...